Mein Warenkorb

STEAP1

STEAP1 Molekülinformation

Englischer NameSix-transmembrane epithelial antigen of the prostate 1Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel7Target-AliasPRSS24,Six-transmembrane epithelial antigen of prostate 1,STEAP,STEAP1,STEAP Family Member 1,Six Transmembrane Epithelial Antigen Of The Prostate 1,STEAP1 Metalloreductase,Six Transmembrane Epithelial Antigen Of The Prostate,Metalloreductase STEAP1,EC 1.16.1.-,EC:1.16.1.-
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Englischer NameSix-transmembrane epithelial antigen of the prostate 1
Target-AliasPRSS24,Six-transmembrane epithelial antigen of prostate 1,STEAP,STEAP1,STEAP Family Member 1,Six Transmembrane Epithelial Antigen Of The Prostate 1,STEAP1 Metalloreductase,Six Transmembrane Epithelial Antigen Of The Prostate,Metalloreductase STEAP1,EC 1.16.1.-,EC:1.16.1.-
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel7
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical

STEAP1 Produktliste

  • Attribut

    Cell (2)Protein (5)

  • Produktbibliothek

    Online (7)

  • Spezies

    Human (6)Rat (1)

  • Etikett

    - (2)His Tag & Strep Tag (2)Tag Free (1)His Tag & Avi Tag & Flag Tag (1)His Tag & Flag Tag (1)

  • Marker

    - (2)Unconjugated (4)Biotin-labeled (1)

STEAP1 Molekülhintergrund

Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is an integral membrane protein that is highly up-regulated on the cell surface of several human cancers, making it a promising therapeutic target to manage these diseases. It shares sequence homology with three enzymes (STEAP2-STEAP4) that catalyze the NADPH-dependent reduction of iron(III). Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target.

STEAP1 Molekülalias

STEAP1, PRSS24, STEAP

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
XaluritamigAMG-509Phase 3 ClinicalAmgen Inc, Xencor IncCastration-Sensitive Prostate Neoplasms; Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing
Details
89Zr-DFO-MSTP2109APhase 2 ClinicalGenentech Inc, Memorial Sloan Kettering Cancer CenterProstatic Neoplasms
Details
STEAP1 CART Cell Therapy(PromiCell)Phase 2 ClinicalFred Hutchinson Cancer Research Center, PromiCell Therapeutics IncProstatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
PRO CAR-201APRO CAR-201APhase 1 ClinicalFred Hutchinson Cancer Research CenterProstatic Neoplasms, Castration-Resistant
Details
ABBV-969ABBV-969; ABBV969Phase 1 ClinicalAbbvie IncProstatic Neoplasms, Castration-Resistant
Details
ADRX-0405ADRX-0405Phase 1 ClinicalAdcentrx Therapeutics IncNeoplasms; Solid tumours
Details
DXC-008DAC-008; DXC-008Phase 1 ClinicalHangzhou Dac Biotech Company LtdProstatic Neoplasms; Sarcoma, Ewing; Solid tumours
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns